Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation.
J Infect Dis
; 186(9): 1270-6, 2002 Nov 01.
Article
en En
| MEDLINE
| ID: mdl-12402196
ABSTRACT
Anticoagulants have gained increasing attention in the treatment of sepsis. This study used danaparoid to investigate the role of factor Xa in endotoxin-induced coagulation and inflammation and its effectiveness when coagulation activation has already occurred. Thirty healthy volunteers were enrolled in the randomized, placebo-controlled trial. Subjects received 2 ng/kg endotoxin and danaparoid 10 min or 3 h thereafter or placebo. Endotoxin increased prothrombin fragment 1+2 (F(1+2)) levels from 0.5 to 7.0 nmol/L at 5 h in the placebo group. Early danaparoid infusion inhibited endotoxin-induced thrombin formation maximum F(1+2) levels reached only 1.8 nmol/L (P<.01, vs. baseline or placebo). Delayed danaparoid infusion effectively blocked further thrombin formation. However, danaparoid did not alter endotoxin-induced changes in the fibrinolytic system, cytokine levels, activation of leukocytes, or tissue factor expression on monocytes. Danaparoid therefore selectively attenuates endotoxin-induced coagulopathy, even with delayed administration when coagulation activation is well under way.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Coagulación Sanguínea
/
Factor X
/
Lipopolisacáridos
/
Sulfatos de Condroitina
/
Citocinas
/
Dermatán Sulfato
/
Heparitina Sulfato
/
Inflamación
/
Anticoagulantes
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Humans
Idioma:
En
Revista:
J Infect Dis
Año:
2002
Tipo del documento:
Article
País de afiliación:
Noruega